# Regina Hodits

> Regina Hodits is a Series B investor at Angelini Ventures backing Health Care and Biotechnology. See 15 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Angelini Ventures](https://shizune.co/investors/profile/angelini-ventures)
- Location: Munich, Germany
- Total investments: 15
- Last investment: May 2026
- Lead investor: 27%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/regina-hodits-270a7481

Regina Hodits is a Series B investor at Angelini Ventures in Munich focused on Health Care and Biotechnology. Regina Hodits joined Wellington Partners in spring 2010 as a part-time advisor and stepped up to General Partner in January 2011. Since 2000, she has become an influential investor in the European venture capital industry, focusing on early-stage and growth deals in Life Sciences. Her industry experience and her strong scientific background willhelp the Wellington Life Sciences team to strengthen its position in the European investment market.Until January 2010, Regina led the life sciences efforts of Atlas Venture in Europe, a leading transatlantic venture capital firm. As a Partner at Atlas Venture, she led numerous financing rounds and was the founding investor in Bicycle Therapeutics, Fibrex, F-star and Jenavalve. In addition, she served on the Board of Egalet, Lumavita, Novamed and Protaffin and is an external director at GlaxoSmithKline's (GSK) Respiratory CEDD. Regina was also on the Board of U3 Pharma, which was acquired by Daiichi Sankyo Co.,Ltd. in 2008.From 2000 to 2004, while working for Apax Partners, she was responsible for healthcare investments in Germany and was closely involved in investments such as Genmab, Silence Therapeutics and Wilex. She started to build her extensive network in the global healthcare industry during her tenure at McKinsey from 1997 to 2000.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 40% |
| Biotechnology | 5 | 33% |
| Medical | 4 | 27% |
| Therapeutics | 4 | 27% |
| Medical Device | 3 | 20% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 6 | 40% |
| Series A | 4 | 27% |
| Series C | 2 | 13% |
| Seed | 1 | 7% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 2 | 13% |
| United States | 2 | 13% |
| Denmark | 1 | 7% |
| Iceland | 1 | 7% |
| Switzerland | 1 | 7% |

6 countries tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Nuclidium | NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics. | $33.6M | Series B | May 28, 2026 |  |
| SNIPR Biome | SNIPR Biome is a operator of a discovery stage biotech company intended to revolutionize the treatment of microbial diseases. The company uses CRISPR technology that can subvert elements of the endogenous bacterial CRISPR machinery to eliminate hazardous bacteria in vivo, providing the health professionals with medicines that selectively target andkill bacteria with specific DNA sequences. | $40.9M | Series B | Aug 07, 2025 |  |
| Nuclidium | NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics. | $131.8M | Series B | Jul 10, 2025 |  |
| Carisma Therapeutics | Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. | $30M | Series C | Sep 21, 2022 |  |
| ImCheck Therapeutics | ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours. | $100M | Series C | Jun 13, 2022 |  |
| Sidekick Health | Sidekick is a patient-centric digital care platform that is scalable across a wide range of chronic illnesses. Sidekick makes healthcare more impactful, accessible, and efficient by developing and delivering digital health products that empower patients and digitize healthcare.The Sidekick platform combines an evidence-based clinical approachwith behavioral economics and gamification. Sidekick's platform approach transforms healthcare experiences, with one platform that integrates multi-chronic condition management and personalized care experiences.Sidekick partners with international pharmaceutical companies, payers and healthcare providers, helping them to put the people they serve first. | $55M | Series B | May 05, 2022 |  |
| Carisma Therapeutics | Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. | $12M | Series B | Mar 01, 2021 |  |
| Carisma Therapeutics | Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. | $47M | Series B | Jan 07, 2021 |  |
| Sidekick Health | Sidekick is a patient-centric digital care platform that is scalable across a wide range of chronic illnesses. Sidekick makes healthcare more impactful, accessible, and efficient by developing and delivering digital health products that empower patients and digitize healthcare.The Sidekick platform combines an evidence-based clinical approachwith behavioral economics and gamification. Sidekick's platform approach transforms healthcare experiences, with one platform that integrates multi-chronic condition management and personalized care experiences.Sidekick partners with international pharmaceutical companies, payers and healthcare providers, helping them to put the people they serve first. | $20M | Series A | Oct 28, 2020 |  |
| ImCheck Therapeutics | ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours. | $52.7M | Series B | Dec 04, 2019 |  |

10 of 15 investments shown.

## Co-investors
- [Agent Capital](https://shizune.co/investors/profile/agent-capital) — VC Fund, 6 deals together
- [HealthCap](https://shizune.co/investors/profile/healthcap) — VC Fund, 6 deals together
- [AbbVie](https://shizune.co/investors/profile/abbvie) — VC Fund, 4 deals together
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 4 deals together
- [MRL Ventures Fund](https://shizune.co/investors/profile/mrl-venture-fund) — VC Fund, 4 deals together
- [TPG Biotech](https://shizune.co/investors/profile/tpg-biotech) — VC Fund, 4 deals together

## About Angelini Ventures

VC Fund · Rome, Italy

Angelini Ventures is an investment firm.

5 contacts available at Angelini Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Nils Bottler | Principal | https://shizune.co/investors/profile/nils-bottler |
| Paolo Di Giorgio | Chief Executive Officer & Managing Director | https://shizune.co/investors/profile/paolo-di-giorgio |
| Regina Hodits | Managing Director | https://shizune.co/investors/profile/regina-hodits |
| Sarah Fox | Investor | https://shizune.co/investors/profile/sarah-fox-5abb |
| Sergio Di Condojanni | Chief Executive Officer | https://shizune.co/investors/profile/sergio-marullo-di-condojanni |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Regina Hodits invest in?

Regina Hodits invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series A stage. Most of the 15 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Regina Hodits last invest?

The most recent investment recorded for Regina Hodits closed in May 2026. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co